HKG: 9995

Company Drug

RemeGen’s Telitacicept Begins Global Phase III Trial for Severe SLE

Fineline Cube Jun 23, 2022

China-based pharmaceutical firm RemeGen (HKG: 9995) has announced the first patient dosing in a global...

Company Drug

Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial

Company Drug

J&J Darzalex Faspro Gets FDA Nod for NDMM D-VRd Regimen

Company Drug

Roche CT-388 Obesity Drug Shows 22.5% Weight Loss in Phase II Trial

Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link